Fast neutron therapy in Tomsk: 40-year experience in cancer treatmnet

Q4 Medicine

Siberian journal of oncology Pub Date : 2024-03-23 DOI:10.21294/1814-4861-2024-23-1-98-108

Z. Startseva, O. Gribova, V. Velikaya, E. S. Sukhikh, V. Lisin, V. Novikov

{"title":"Fast neutron therapy in Tomsk: 40-year experience in cancer treatmnet","authors":"Z. Startseva, O. Gribova, V. Velikaya, E. S. Sukhikh, V. Lisin, V. Novikov","doi":"10.21294/1814-4861-2024-23-1-98-108","DOIUrl":null,"url":null,"abstract":"The purpose of the study was to evaluate the efficacy of neutron therapy (NT) for salivary gland cancer and recurrent breast cancer. Material and Methods. The study included 130 patients with salivary gland cancer and 125 patients with recurrent breast cancer. Fast neutron therapy using U-120 cyclotron was given to the patients of the study group. Patients of the control group received standard radiotherapy (external beam radiotherapy). Results. Among patients with salivary gland cancer, a recurrence rate was significantly lower in patients who received a postoperative course of NT compared to patients of the control group (21.1 vs 45 %, p<0.05). The five-year overall survival rates were 73.8 ± 9.5 % and 43.2 ± 9.4 % in the study group and the control group, respectively (p<0.05). The five-year disease-free survival rates were 65.6 ± 7.5 % and 34.8 ± 9.1 % in the study and control groups, respectively (p<0.05). In patients with recurrent breast cancer, a significant increase in the frequency of complete regression in the study group compared to the control group was observed (91.8 vs 51.3 %, p<0.05). Ten-year survival rates in patients with no evidence of re-recurrence were 77.4 ± 8.7 % and 44.7 ± 8.8 % in the study group and the control group, respectively (p<0.05). Conclusion. The study demonstrated efficacy of fast neutron therapy in patients with salivary gland cancer and recurrent breast cancer. Neutron therapy did not result in serious complications, improved survival of the patients and decreased the recurrence rate compared with standard radiotherapy.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":" 78","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Siberian journal of oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21294/1814-4861-2024-23-1-98-108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The purpose of the study was to evaluate the efficacy of neutron therapy (NT) for salivary gland cancer and recurrent breast cancer. Material and Methods. The study included 130 patients with salivary gland cancer and 125 patients with recurrent breast cancer. Fast neutron therapy using U-120 cyclotron was given to the patients of the study group. Patients of the control group received standard radiotherapy (external beam radiotherapy). Results. Among patients with salivary gland cancer, a recurrence rate was significantly lower in patients who received a postoperative course of NT compared to patients of the control group (21.1 vs 45 %, p<0.05). The five-year overall survival rates were 73.8 ± 9.5 % and 43.2 ± 9.4 % in the study group and the control group, respectively (p<0.05). The five-year disease-free survival rates were 65.6 ± 7.5 % and 34.8 ± 9.1 % in the study and control groups, respectively (p<0.05). In patients with recurrent breast cancer, a significant increase in the frequency of complete regression in the study group compared to the control group was observed (91.8 vs 51.3 %, p<0.05). Ten-year survival rates in patients with no evidence of re-recurrence were 77.4 ± 8.7 % and 44.7 ± 8.8 % in the study group and the control group, respectively (p<0.05). Conclusion. The study demonstrated efficacy of fast neutron therapy in patients with salivary gland cancer and recurrent breast cancer. Neutron therapy did not result in serious complications, improved survival of the patients and decreased the recurrence rate compared with standard radiotherapy.

查看原文本刊更多论文

托木斯克的快中子疗法：40 年的癌症治疗经验

本研究旨在评估中子疗法（NT）对唾液腺癌和复发性乳腺癌的疗效。材料和方法。研究对象包括130名唾液腺癌患者和125名复发性乳腺癌患者。研究组患者使用 U-120 回旋加速器进行快中子治疗。对照组患者接受标准放射治疗（体外放射治疗）。研究结果在唾液腺癌患者中，术后接受NT治疗的患者的复发率明显低于对照组患者（21.1%对45%，P<0.05）。研究组和对照组的五年总生存率分别为 73.8 ± 9.5 % 和 43.2 ± 9.4 %（P<0.05）。研究组和对照组的五年无病生存率分别为 65.6 ± 7.5 % 和 34.8 ± 9.1 %（P<0.05）。在复发性乳腺癌患者中，研究组与对照组相比，完全消退率显著增加（91.8% 对 51.3%，P<0.05）。研究组和对照组无复发迹象患者的十年生存率分别为 77.4 ± 8.7 % 和 44.7 ± 8.8 %（P<0.05）。结论该研究证明了快中子疗法对唾液腺癌和复发性乳腺癌患者的疗效。与标准放疗相比，中子疗法未导致严重并发症，提高了患者的生存率，降低了复发率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Siberian journal of oncology Medicine-Oncology

CiteScore

0.40

自引率

0.00%

发文量

117

审稿时长

8 weeks

期刊介绍： The main objectives of the journal are: -to promote the establishment of Russia’s leading worldwide positions in the field of experimental and clinical oncology- to create the international discussion platform intended to cover all aspects of basic and clinical cancer research, including carcinogenesis, molecular biology, epidemiology, cancer prevention, diagnosis and multimodality treatment (surgery, chemotherapy, radiation therapy, hormone therapy), anesthetic management, medical and social rehabilitation, palliative care as well as the improvement of life quality of cancer patients- to encourage promising young scientists to be actively involved in cancer research programs- to provide a platform for researches and doctors all over the world to promote, share, and discuss various new issues and developments in cancer related problems. (to create a communication platform for the expansion of cooperation between Russian and foreign professional associations).- to provide the information about the latest worldwide achievements in different fields of oncology The most important tasks of the journal are: -to encourage scientists to publish their research results- to offer a forum for active discussion on topics of major interest - to invite the most prominent Russian and foreign authors to share their latest research findings with cancer research community- to promote the exchange of research information, clinical experience, current trends and the recent developments in the field of oncology as well as to review interesting cases encountered by colleagues all over the world- to expand the editorial board and reviewers with the involvement of well-known Russian and foreign experts- to provide open access to full text articles- to include the journal into the international database- to increase the journal’s impact factor- to promote the journal to the International and Russian markets